11:58 AM EDT, 06/24/2024 (MT Newswires) -- Regenxbio ( RGNX ) said Monday that it started the enrollment of a new group of patients aged 1 year to 3 years old for the phase 1/2 trial of RGX-202 in boys with Duchenne muscular dystrophy.

The company said it expects to enroll up to five patients under the new group while enrollment continues for patients aged 4 years to 11 years old.

Regenxbio ( RGNX ) also said an end-of-phase 2 meeting with the US Food and Drug Administration in July is expected to help finalize the pivotal trial design, which is targeted to start in late Q3 or early Q4.

The company said it targets to release initial data within the second half of the year.

Shares of Regenxbio ( RGNX ) were up more than 4% in recent trading.

Price: 12.55, Change: +0.53, Percent Change: +4.41